Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $2.77, but opened at $2.99. Gossamer Bio shares last traded at $3.04, with a volume of 4,192,385 shares traded.
Analysts Set New Price Targets
A number of equities analysts have recently commented on GOSS shares. Wall Street Zen raised shares of Gossamer Bio from a "sell" rating to a "hold" rating in a report on Saturday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Gossamer Bio in a report on Thursday. Wedbush raised their price objective on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday, August 6th. Finally, Scotiabank started coverage on shares of Gossamer Bio in a report on Monday, July 14th. They set a "sector outperform" rating and a $11.00 price objective for the company. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $8.50.
Check Out Our Latest Stock Report on Gossamer Bio
Gossamer Bio Stock Down 8.1%
The stock has a market capitalization of $723.07 million, a P/E ratio of -5.13 and a beta of 1.95. The firm's fifty day moving average is $2.08 and its 200-day moving average is $1.46. The company has a current ratio of 4.40, a quick ratio of 4.40 and a debt-to-equity ratio of 6.70.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million during the quarter, compared to the consensus estimate of $4.12 million. As a group, equities research analysts predict that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.
Institutional Investors Weigh In On Gossamer Bio
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new stake in Gossamer Bio in the 2nd quarter valued at about $129,000. Corient Private Wealth LLC increased its position in Gossamer Bio by 8.9% in the 2nd quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company's stock valued at $4,543,000 after acquiring an additional 302,200 shares in the last quarter. Lazard Asset Management LLC increased its position in Gossamer Bio by 53.9% in the 2nd quarter. Lazard Asset Management LLC now owns 67,362 shares of the company's stock valued at $82,000 after acquiring an additional 23,601 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in Gossamer Bio in the 2nd quarter valued at about $534,000. Finally, Banco BTG Pactual S.A. acquired a new stake in Gossamer Bio in the 2nd quarter valued at about $27,000. Institutional investors and hedge funds own 81.23% of the company's stock.
Gossamer Bio Company Profile
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Featured Stories
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
